Topic: mantle cell lymphoma
Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.
To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.
AstraZeneca is rolling with a series of trial wins for Calquence in CLL. Will those data help the drug challenge Imbruvica’s blockbuster sales?
When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.
Chasing big fish in the BTK inhibitor market, AstraZeneca’s Calquence was looking for a leg up. New clinical data show promise in leukemia.
Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.
The CD22-directed cytotoxin treatment is AstraZeneca's second approved blood cancer asset, with peak sales estimated at about $500 million.
With just-arrived competition in mantle cell lymphoma, J&J’s Imbruvica has snagged reimbursement backing in an important new market.
J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.